WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has entered into an exclusive distributorship agreement with Ninelj Saez, a company located in Lima, Peru, for the sale and distribution of its Dri-Sate Dry Acid Concentrate Mixing System and its bicarbonate powder products.

The agreement specifies Ninelj Saez to be the exclusive sales agent and distributor for Rockwell Medical Technologies, Inc. in Peru. According to the agreement, Ninelj Saez will purchase a minimum of twelve ocean-freight containers of the Company's Dri-Sate Dry Acid Concentrate and bicarbonate powder products during the next twelve months.

Robert L. Chioini, Chairman, CEO and President of Rockwell Medical Technologies, Inc., stated, "We are pleased to have Ninelj Saez represent us in Peru. Our penetration into the foreign markets with our Dri-Sate Dry Acid continues to grow and we will continue to evaluate distributor relationships which will allow us to increase our international market share."

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has recently added two key managers to its management team.

Mr. Rudy Merriweather, Vice President of Manufacturing, and Mr. Evan Moilan, Plant and Operations Manager, Southwest Division, will facilitate the Company's manufacturing and plant expansion.

Rockwell recently announced $2 million in equity capital financing to fund its expansion and development efforts. The Company expects to close on its equity financing on or around the 22nd of December. The Company's strategy is to expand and strengthen its market presence utilizing regional manufacturing sites throughout the United States. The Company operates one plant in the Midwest in Wixom, Michigan and has added a second manufacturing facility in the Southwest in Grapevine, Texas, near Dallas.

Mr. Robert L. Chioini, Chairman, CEO and President stated, “We are pleased to add these two very experienced manufacturing managers to our team. Their in-depth experience in coordinating plant start-up and manufacturing expansion will be extremely beneficial in facilitating Rockwell's growth strategy.”

Mr. Rudy Merriweather has more than 25 years of extensive chemical manufacturing experience including plant start-up and production expansion. He previously served for eight years as Director of Manufacturing for ITW Foamseal where its production volume tripled during his tenure. In addition, Mr. Merriweather's background includes over 16 years with BASF where he held several key manufacturing plant management positions in its Polymer division. Mr. Merriweather holds a Bachelors of Science Degree in Chemical Engineering from Wayne State University.

Mr. Evan Moilan has more than 25 years of nutritional packaging and manufacturing experience including plant start-up and production expansion. Mr. Moilan was employed with the Wyeth Nutritional division of American Home Products for 13 years where he last served as Technical Director in charge of manufacturing. He also spent ten years with Mead Johnson, a subsidiary of Bristol-Myers Squibb, in a variety of manufacturing management roles. Mr. Moilan holds a Bachelor of Science Degree in Food Technology from Texas Tech University.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. (Nasdaq: RMTI), a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, made a statement today clarifying that the expiration date of its warrants is January 26, 2002. The Company's publicly traded warrants have a trading term of three years from January 26, 1999 and expire on January 26, 2002.

The Company has received reports from several investors and brokers that erroneous information regarding the expiration date of the warrants may have inadvertently been provided to investors through certain investor information services. The Company's audited financial statements for 1999 and its 1999 10-KSB filing dated March 30, 2000 with the Securities and Exchange Commission accurately describes the warrant terms, including their expiration date of January 26, 2002. In addition, the Company has contacted certain reporting services to clarify the warrant terms and those reporting services indicated that the information has been corrected.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that its sales revenue in the third quarter 2000 increased 24% over its third quarter sales in 1999. Sales increased by $ 380,000 to $ 1,984,000 compared to the third quarter of 1999. The Company's Dri-Sate Dry Acid Concentrate unit sales volume increased by 100% in the third quarter compared to the third quarter of 1999. Loss per share was ($.06) for the third quarter versus ($.05) in the third quarter of 1999.

For the nine months ending September 30, 2000, the Company's revenues increased 12.3% over the first nine months of 2000. Sales increased $ 583,000 to $ 5.3 million over the first nine months of 2000. The Company realized a gross profit dollar increase of 21% or $ 104,000 compared to the same nine month period last year. Operating margins improved by 4.5 points to sales in comparison to 1999's first nine months. Year to date the net loss per share of $ (.18) improved by $ .02 per share.

Mr. Robert L. Chioini, Chairman, CEO, and President of Rockwell Medical Technologies, Inc. said, “We are pleased not only by the increase in sales revenue but by the favorable market acceptance of our Dri-Sate product line. We continue to see strong interest for Dri-Sate both in the U.S. and international markets and we are in the process of automating our Dri-Sate production and packaging process which we anticipate will contribute to improved operating margins in the future. New customer orders remain strong and as we continue to aggressively penetrate the market we expect to see an increase in sales revenue and overall market share.”

Thomas E. Klema, Vice President and Chief Financial Officer stated, “We have added new business in the South and Southwestern markets in advance of opening our second manufacturing plant in Texas. In the short run, we are incurring higher production and distribution costs to service this business, however, we anticipate improved operating efficiencies and margins once our facility comes on line in early 2001."

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- The Wall Street Transcript has published an in-depth interview with Robert L. Chioini, CEO of Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, in which he talks at length about the company's future.

The entire 1,875 word interview is available online at Rockwell's web site (interview text) Mr. Chioini gives an overview of the company. "In short, Rockwell manufactures and distributes dialysis concentrates in both liquid and powder form, carries an ancillary product line which compliments its core offering and provides exceptional delivery service by distributing product directly to the dialysis provider (the dialysis clinic) using its own trucks."

Mr. Chioini explains, "Our measure of success will come from capturing the national concentrate market by expanding with multiple manufacturing sites and by continuing to penetrate that market with our innovative Dri-Sate Dry Acid Concentrate."

Looking forward, Mr. Chioini states, "It's a recession-proof market and estimates are that there will be more than 600,000 dialysis patients in the U.S. over the next four years, and someone has to service that market."

The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors for over 37 years. The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies Inc. (Nasdaq: RMTI), a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that its sales revenue in the second quarter increased 10% over its second quarter sales in 1999.

Gross profit increased by 30% compared to the second quarter of 1999. Loss per share decreased to ($.07) in the second quarter of 2000 from ($.08) in the second quarter of 1999.

The Company's Dri-Sate Dry Acid Concentrate product line continued to increase in sales. Unit sales volume of Dri-Sate Dry Acid increased by 74% in the second quarter of 2000 compared to the second quarter of 1999. The Company's product mix continues to shift towards its Dri-Sate Dry Acid Concentrate product line and away from liquid acid concentrate packaged in 55 gallon drums. The majority of the Company's new customers have selected Dri-Sate Dry Acid Concentrate.

Mr. Robert L. Chioini, Chairman, CEO, and President of Rockwell Medical Technologies, Inc. said, "We are encouraged by the strong market acceptance of our Dri-Sate product line. As we continue to add new customers and we begin delivering products to additional clinics of our current customers, we expect to see an increase in sales revenue and overall market share." Mr. Chioini also stated, "During the second quarter we made investments in marketing and advertising which we believe will contribute to increased market share. We anticipate higher revenues for the future which will also lead to improved operating margins."

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies Inc. (Nasdaq: RMTI), a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported that in the first quarter 2000 it reduced its loss by $120,000 compared to the first quarter of 1999. The Company reported that their loss narrowed in the first quarter 2000 to $238,100, over the loss in the first quarter 1999 of $358,100. The Company reported net sales of $1,634,200, while its gross profit increased from $148,000 first quarter 1999 to $197,400 in first quarter 2000. The Company's loss per share improved by $.02 to ($.05) per share compared to ($.07) per share in the first quarter of 1999.

The Company also experienced a substantial sales revenue increase in the first quarter 2000 with its Dri-Sate Dry Acid Concentrate as volume more than tripled from the year earlier period. The Company's liquid acid drum volume declined due to the reduction of certain distributor business that did not meet the Company's margin targets at the end of the first quarter of 1999. Excluding the distributor volume reduction, the Company's liquid acid sales remained static while its Dri-Sate Dry Acid Concentrate product line sales increased to over 40% of total acid concentrate sales.

Robert L. Chioini, Chairman, President and Chief Executive Officer, stated "The Company's results were in line with our expectations following a strong fourth quarter in 1999. Fourth quarter 1999 sales included increased inventory stocking by some of our customers as a precautionary measure related to potential Year 2000 supply chain disruptions, and as result we experienced a lower rate of sales growth in the first quarter of 2000." Mr. Chioini continued, "During the first quarter Rockwell secured supply commitments from several customers which will enable the Company to increase its sales revenue and to further penetrate the market."

Rockwell Medical Technologies, Inc., is a leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from End Stage Renal Disease (ESRD). There are approximately 300,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies Inc. (Nasdaq: RMTI), a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has entered into a Preferred Supplier Contract with Total Renal Care, Inc. which will cover Total Renal Care dialysis clinics located in the Midwest and Northeast.

Total Renal Care Holdings, Inc., based in Torrance, California, is the nation's second-largest provider of dialysis services for patients suffering from chronic kidney failure. The Company owns and operates kidney dialysis centers and home peritoneal dialysis programs domestically in 32 states, as well as Washington, D.C. It also provides acute hemodialysis services to inpatients at approximately 320 hospitals. As of March 31, 2000, Total Renal Care operated 484 outpatient dialysis facilities serving 40,000 patients, including 4,200 patients in 52 centers under management. Under the Agreement, Rockwell will supply TRC dialysis facilities located in the Midwest and Northeast, which consists of approximately 148 dialysis clinics. Rockwell has agreed to supply these TRC facilities with the dialysate, which is used in the dialysis treatments for patients suffering from chronic kidney failure. Rockwell currently services approximately 29 TRC dialysis clinics.

Robert L. Chioini, Chairman, CEO and President of Rockwell Medical Technologies, Inc., stated, "We are very pleased with this mutually beneficial relationship with TRC. This commitment is a testament to our ability to bring added value to the dialysis provider and it should allow us to increase sales revenue, improve profit margins, and gain greater presence through-out the entire market."

Rockwell Medical Technologies, Inc., is a leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from End Stage Renal Disease (ESRD). There are approximately 300,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

> WIXOM, Mich. -- Rockwell Medical Technologies Inc. (Nasdaq: RMTI), a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has entered into a national Supply Contract with National Nephrology Associates, Inc. (NNA).

NNA is a nephrology services company, which focuses on providing care to patients with kidney disease, including patients suffering from chronic kidney failure. NNA currently delivers dialysis and related healthcare services to approximately 3500 dialysis patients through a nationwide renal care delivery network comprised of approximately 63 dialysis clinics in 12 states. Currently, Rockwell supplies 23 NNA dialysis clinics.

Rockwell will supply NNA dialysis clinics with dialysate and other ancillary items, which are used in the dialysis treatments for patients suffering from chronic kidney failure. NNA is expected to purchase, on a national level, Rockwell's Dri-Sate Dry Acid Concentrate and Bicarbonate Powder as well as other ancillary dialysis products for all of its dialysis facilities.

Robert L. Chioini, Chairman, CEO and President of Rockwell Medical Technologies, Inc., stated, "This Supply Contract with NNA strengthens Rockwell's strategy of capturing significant market share with expanding dialysis providers who offer high-quality treatment for patients suffering from chronic kidney failure. NNA's significant concentration of dialysis patients in the southwest should allow us to quickly gain a strong presence there for our new manufacturing plant in Texas."

Rockwell Medical Technologies, Inc., is a leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from End Stage Renal Disease (ESRD). There are approximately 300,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies Inc. (Nasdaq: RMTI), a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has leased a second manufacturing site, located in Texas. Rockwell already has a manufacturing site located in Michigan.

The new manufacturing plant is located in Grapevine, TX, near Dallas, and is approximately 51,000 square feet. It will have initial capacity to service 65,000 hemodialysis patients annually and it will produce Rockwell's Liquid Acid Concentrate, Dri-Sate Dry Acid Concentrate, SteriLyte™ Liquid Bicarbonate and Powder Bicarbonate. Rockwell will also distribute ancillary dialysis products from the location. Rockwell expects to begin shipping product during the third quarter of 2000.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell, stated, "This second manufacturing plant will give Rockwell a strong presence in the Southwest. It will allow us to increase our sales revenue, improve our profit margins and gain a greater presence in the dialysis provider market in that region."

Rockwell Medical Technologies, Inc., is a leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from End Stage Renal Disease (ESRD). There are approximately 300,000 dialysis patients in the United States and the incidence of ESRD has increased 8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies Inc. (Nasdaq: RMTI), a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has appointed two new independent directors to its Board of Directors and that two previous members have resigned from the Board of Directors of the Company.

Joining the Rockwell Board of Directors are Mr. Kenneth L. Holt and Mr. Ronald D. Boyd. Mr. Holt and Mr. Boyd have combined business experience of over 33 years in the hemodialysis industry. Mr. Gary Lewis, the Board's former Chairman, and Mr. Norman McKee have elected to resign from the Board in order to pursue other business interests.

Mr. Robert L. Chioini, President & CEO, will assume the additional duties of Chairman of the Board of Directors. Mr. Chioini stated, "We are delighted to have two hemodialysis business professionals of the caliber of Mr. Boyd and Mr. Holt join Rockwell's Board of Directors. We believe their industry knowledge, experience and perspectives will add immediate and ongoing value to the Company. We look forward to their contributions to our continued growth and development."

Mr. Holt is a founder and Co-owner of Savannah Dialysis Specialists, LLC, a disease management company specializing in the treatment of end-stage renal disease, and has served as the Managing Partner since October of 1999. From 1996 to October 1999, Mr. Holt served as Vice President for Gambro Healthcare, in its Carolinas Region, and held the same position at Vivra Renal Care, its predecessor company which was acquired in 1997 by Gambro (Gambro is currently the second largest integrated dialysis provider, manufacturer and distributor of renal care products in the United States). From 1986 to 1996, Mr. Holt was also the founder, Co-owner and Managing Partner in five dialysis clinics servicing approximately 350 dialysis patients.

Mr. Boyd is a founder and Co-owner of Classic Medical, Inc., a dialysis and medical products company, and has served as the Executive Vice President since the Company's inception in November of 1993. From May 1993 to November 1993, Mr. Boyd served as a consultant for Dial Medical of Florida, Inc., a manufacturer and distributor of dialysis products. From 1990 to 1993, Mr. Boyd served as a Regional Sales Manager for Future Tech, Inc., a dialysis products distributor.

Rockwell Medical Technologies, Inc., is a leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from End Stage Renal Disease (ESRD). There are approximately 300,000 dialysis patients in the United States and the incidence of ESRD has increased 8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a leading innovative dialysis concentrate manufacturer, announced today that it has elected not to renew Wall Street Partners, Inc.'s consulting agreement with the Company. Wall Street Partners, Inc. provided financial and management services during a consulting agreement ending December 31, 1999. The Company paid Wall Street Partners, Inc. $ 240,000 under the agreement during 1999. The agreement was not renewed effective January 1, 2000.

The Company previously reported that for the fourth quarter ended December 31, 1999, the Company incurred a net loss of $ 88,800 or $ (.02) per share which represented a 75% decrease in its loss per share from the fourth quarter of 1998. Revenues for the fourth quarter of 1999 increased by 25% from the year earlier quarter. Similarly, Rockwell's sales for 1999 were $ 6.7 million and represented an increase of 27% over 1998. The Company reported a loss of $ 1,071,000 in 1999. Earnings per share for the year ended December 31, 1999 were $ .19 better than 1998 with an overall loss of $ (.22) per share in 1999 compared to a loss of $ (.41) per share in 1998.

Rockwell Medical Technologies, Inc., is a leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from End Stage Renal Disease (ESRD). There are approximately 300,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. (Nasdaq: RMTI) announced today that its fourth quarter 1999 loss per share decreased by 75% to a loss of $.02 per share from a loss of $ .08 per share in the fourth quarter of 1998. Revenues increased by 25 % in the fourth quarter of 1999 over the fourth quarter of 1998. Sales increased by $.4 million to $ 1.96 million compared to the fourth quarter of 1998. The Company reported a loss of $ 88,800 for the fourth quarter compared to $ 371,500 in the fourth quarter of 1998.

Rockwell's fourth quarter earnings improvement was the result of increased sales volume coupled with higher gross profit margins. Gross profit margins increased to 21% from 5.4% in the fourth quarter of 1998 with gross profit up $ 328,900.

Rockwell's results for the year ended December 31, 1999 included a 27 % sales increase with 1999 sales of $ 6.7 million compared to $ 5.3 million in 1998. Gross profit increased by $ 1.1 million to $ .9 million from a deficit of $.2 million with overall gross profit margins of 13.6 % compared with a gross margin deficit of (3.2%) in 1998. The Company's l999 loss was $ 1,071,300 compared with a loss of $ 1,928,600 in 1998. Loss per share improved by $.19 to ($.22) in 1999 compared to ($.41) in 1998.

Vice President and Chief Financial Officer, Thomas E. Klema stated "Our fourth quarter results represented the best quarter in the Company's history with continuing improvement in sales and gross profit margins. Over the last six months, the Company has been cash flow neutral due to improving results and good working capital management efforts. The Company finished the year with $ 1.1 million dollars in cash and has no long term debt or bank loans."

Robert L. Chioini, President and Chief Executive Officer, stated "Rockwell experienced an outstanding fourth quarter with significant sales growth, substantial margin improvement and increased market penetration of the Company's products. We have now had eight quarters of positive sales and earnings improvement since going public in early 1998. We are pleased with our overall performance in 1999 including the successful introduction of our dry acid concentrate line which has served to reduce our customers costs, improve our operating efficiency and resulted in substantial sales growth for the Company."

Rockwell Medical Technologies, Inc., is a leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from End Stage Renal Disease (ESRD). There are approximately 300,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.